Abstract
The recent announcement that the third-generation epidermal growth factor receptor (EGFR) inhibitor, osimertinib, will be publicly funded in New Zealand is welcome news for patients and medical professionals alike.
- Record Identifier
- 9926559677201891
- Title
- The case for publicly funding lorlatinib
- Creators
- John C Ashton
- Publication Details
- New Zealand medical journal, Vol.137(1601), p.77
- Academic Unit
- Pharmacology and Toxicology
- Publisher
- Pasifika Medical Association Group
- Date published ; e-published
- 23/08/2024
- Language
- English
- Resource Type ; Subtype
- Letter/Communication